Literature DB >> 25619976

Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists.

Daniel M Berney1, Ferran Algaba2, Mahul Amin3, Brett Delahunt4, Eva Compérat5, Jonathan I Epstein6, Peter Humphrey7, Mohammed Idrees8, Antonio Lopez-Beltran9, Cristina Magi-Galluzzi10, Gregor Mikuz11, Rodolfo Montironi12, Esther Oliva13, John Srigley14, Victor E Reuter15, Kiril Trpkov16, Thomas M Ulbright8, Murali Varma17, Clare Verrill18, Robert H Young13, Ming Zhou19, Lars Egevad20.   

Abstract

AIMS: The handling and reporting of testicular tumours is difficult due to their rarity. METHODS AND
RESULTS: A survey developed by the European Network of Uro-Pathology (ENUP) and sent to its members and experts to assess the evaluation of testicular germ cell tumours. Twenty-five experts and 225 ENUP members replied. Areas of disagreement included immaturity in teratomas, reported by 32% of experts but 68% of ENUP. Although the presence of rete testis invasion was reported widely, the distinction between pagetoid and stromal invasion was made by 96% of experts but only 63% of ENUP. Immunohistochemistry was used in more than 50% of cases by 68% of ENUP and 12% of experts. Staging revealed the greatest areas of disagreement. Invasion of the tunica vaginalis without vascular invasion was interpreted as T1 by 52% of experts and 67% of ENUP, but T2 by the remainder. Tumour invading the hilar adipose tissue adjacent to the epididymis without vascular invasion was interpreted as T1: 40% of experts, 43% of ENUP; T2: 36% of experts, 30% of ENUP; and T3: 24% of experts, 27% of ENUP.
CONCLUSIONS: There is remarkable consensus in many areas of testicular pathology. Significant areas of disagreement included staging and reporting of histological types, both of which have the potential to impact on therapy.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  classification; consensus; germ cell tumour; rete testis; staging; testis

Mesh:

Year:  2015        PMID: 25619976      PMCID: PMC5026308          DOI: 10.1111/his.12657

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  37 in total

Review 1.  Ten testicular trapdoors.

Authors:  R Rajab; D M Berney
Journal:  Histopathology       Date:  2008-03-12       Impact factor: 5.087

Review 2.  Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?

Authors:  Thomas Powles
Journal:  Hematol Oncol Clin North Am       Date:  2011-06       Impact factor: 3.722

3.  The continued value of central histopathological review of testicular tumours.

Authors:  R J Delaney; C D Sayers; M A Walker; G M Mead; J M Theaker
Journal:  Histopathology       Date:  2005-08       Impact factor: 5.087

4.  Rete testis invasion by malignant germ cell tumor and/or intratubular germ cell neoplasia: what is the significance of this finding?

Authors:  Adam P Vogt; Zhengjia Chen; Adeboye O Osunkoya
Journal:  Hum Pathol       Date:  2010-06-22       Impact factor: 3.466

5.  Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors.

Authors:  Asli Yilmaz; Tina Cheng; Jianguo Zhang; Kiril Trpkov
Journal:  Mod Pathol       Date:  2012-12-14       Impact factor: 7.842

6.  The value of central histopathological review of testicular tumours before treatment.

Authors:  A H Lee; G M Mead; J M Theaker
Journal:  BJU Int       Date:  1999-07       Impact factor: 5.588

Review 7.  The most common, clinically significant misdiagnoses in testicular tumor pathology, and how to avoid them.

Authors:  Thomas M Ulbright
Journal:  Adv Anat Pathol       Date:  2008-01       Impact factor: 3.875

8.  SALL4 is a novel diagnostic marker for testicular germ cell tumors.

Authors:  Dengfeng Cao; Jianping Li; Charles C Guo; Robert W Allan; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

9.  Mitotic count in seminomas--an unreliable criterion for distinguishing between classical and anaplastic types.

Authors:  A R von Hochstetter
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

10.  Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

Authors:  J Aparicio; P Maroto; X García del Muro; A Sánchez-Muñoz; J Gumà; M Margelí; A Sáenz; N Sagastibelza; D Castellano; J A Arranz; D Hervás; R Bastús; A Fernández-Aramburo; J Sastre; J Terrasa; M López-Brea; J Dorca; D Almenar; J Carles; A Hernández; J R Germà
Journal:  Ann Oncol       Date:  2014-09-10       Impact factor: 32.976

View more
  7 in total

1.  Testicular germ cell tumors: the changing role of the pathologist.

Authors:  Andrea Ronchi; Francesca Pagliuca; Renato Franco
Journal:  Ann Transl Med       Date:  2019-09

Review 2.  Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Authors:  Peter Lesko; Michal Chovanec; Michal Mego
Journal:  Nat Rev Urol       Date:  2022-08-26       Impact factor: 16.430

Review 3.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

4.  Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?

Authors:  A Radtke; J-F Cremers; S Kliesch; S Riek; K Junker; S A Mohamed; P Anheuser; G Belge; K-P Dieckmann
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-17       Impact factor: 4.553

5.  Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.

Authors:  Gazanfer Belge; Finja Hennig; Cansu Dumlupinar; Francesca Grobelny; Klaus Junker; Arlo Radtke; Klaus-Peter Dieckmann
Journal:  Oncotarget       Date:  2020-04-21

6.  Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1.

Authors:  Klaus-Peter Dieckmann; Cansu Dumlupinar; Arlo Radtke; Cord Matthies; Renate Pichler; Pia Paffenholz; Jörg Sommer; Alexander Winter; Friedemann Zengerling; Finja Hennig; Christian Wülfing; Gazanfer Belge
Journal:  World J Urol       Date:  2021-11-14       Impact factor: 4.226

7.  Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study.

Authors:  Thomas Wagner; Birgitte Grønkær Toft; Birte Engvad; Jakob Lauritsen; Michael Kreiberg; Mikkel Bandak; Josephine Rosenvilde; Ib Jarle Christensen; Anette Pedersen Pilt; Daniel Berney; Gedske Daugaard
Journal:  BMJ Open       Date:  2019-10-31       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.